⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VRDN News
Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
businesswire.com
VRDN
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
businesswire.com
VRDN
Form 8-K
sec.gov
VRDN
4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
globenewswire.com
UPC
NTHI
DCOY
VRDN
Form 8-K
sec.gov
VRDN
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
businesswire.com
VRDN
Form 8-K
sec.gov
VRDN
Form 8-K
sec.gov
VRDN
Form 8-K
sec.gov
VRDN
Form 8-K
sec.gov
VRDN